602 imported drugs and anticancer drugs to cut prices | the highest drop of 60%

Medical Network August 31 news Anti-cancer drug price reduction is still continuing.

On August 29, the “Notice on Implementing the Price Reduction of Imported Drugs and Anticancer Drugs (Second Batch)” issued by the Hainan Provincial Public Resource Trading Center showed that for Pfizer Pharmaceutical Co., Ltd., etc. enterprise Submitted 583 import drugs and anti-cancer drug price reduction applications for publicity. After the expiration of the publicity period, the province will be concentrated purchase The service platform carries out price adjustment. On August 28th, the platform also issued price adjustments for the 19 pre-national anti-cancer drugs involved in the notification of the National Medical Insurance Bureau in the province's centralized drug procurement service platform. The total number of price reduction drugs reached 602.

It is worth mentioning that in the price-cutting enterprises, not only foreign-funded drugs, but also domestically-made drugs are included. 'Under the policy, the price cut will continue.' Industry professionals told reporters.

According to the “Notice on Implementing the Price Reduction of Imported Drugs and Anticancer Drugs (Second Batch)” issued by the Hainan Provincial Public Resource Transaction Service Center, only 31 drugs fell more than 10%, and most of the drugs fell less. Less than 4%.

Among them, docetaxel injection produced by Qilu Pharmaceutical, calcium leucovorin for injection, nedaplatin for injection, decitabine for injection produced by Shandong New Times Pharmaceutical Co., Ltd., vinorelbine tartar produced by Shuanglu Pharmaceutical Bin injection has a large decline.

The dosage of docetaxel (0.5ml: 20mg) produced by Qilu Pharmaceutical decreased from 309 yuan / support to 122.36 yuan / support, a decrease of about 60.4%, docetaxel injection (1ml: 40mg * 1) from 546 yuan / Branch fell to 262.87 yuan / support, a decrease of 51.8%.

Shanxi Xinshi Pharmaceutical produced injectable decitabine from 9,200 yuan / bottle to 4,950 yuan / bottle, a decrease of about 46.2%.

It is worth mentioning that the imported drugs of the above varieties have been reduced.

On August 9th, Shanghai Sunshine Pharmaceutical Purchasing Network issued the “Notice on Adjusting the Price of Some Drugs”. The “Notice” shows that Sanofi Pharmaceutical Co., Ltd. and Pierre Faber Medical Technology Co., Ltd. proposed to adjust the price of some drugs. According to the company's application, it is agreed to adjust the bid price of docetaxel injection and vinorelbine tartrate injection.

In addition, the imported drugs for injectable decitabine have been reduced. For example, the winning bidder is Xi'an Yangsen Pharmaceutical Co., Ltd., and the production company is Pharmachemie BV. The injection of decitabine is reduced from 10327.22 yuan/box to 4996 yuan/box, and the price is reduced by about 5331. Yuan / box, the decline was 51.6%. At that time, this drug has attracted market attention both in terms of price reduction and price reduction.

Promoting drug prices, especially the price reduction of anticancer drugs, is still the focus of the next regulatory work.

On August 28, the General Office of the State Council issued the Notice on Printing and Distributing the Key Tasks for Deepening the Reform of the Medical and Health System in the Second Half of 2018, which pointed out that in conjunction with the anti-cancer drug tax reduction policy, the provinces (autonomous regions, municipalities directly under the Central Government) will be promoted to carry out medical insurance catalogues. Centralized procurement of anticancer drugs, advancing medical insurance access approval for exclusive anticancer drugs outside the medical insurance catalogue. Launching a pilot program for centralized drug procurement in the country, significantly reducing drug prices.

In some areas, special centralized procurement of provincial anticancer drugs has been launched.

On August 30th, Shanghai Sunshine Pharmaceutical Purchasing Network issued the “Notice on the Centralized Anti-cancer Drugs Centralized Procurement in the City”, requiring relevant production enterprises to actively adjust to Shanghai on the basis of national anti-cancer drug tax reduction. The price of the city.

Shanghai will classify drugs that are subject to price adjustment into four categories. Among them, anti-cancer drugs belonging to 'other medical insurance drugs' will not be submitted to the "Sunshine Platform Drug Price Adjustment Record Form" before September 30, 2018, and will be included in the open source bargaining procurement scope. And set the 'red line' bargaining lock according to the above-mentioned price adjustment filing conditions. If the bargaining result is higher than the price adjustment filing requirement, it will not be verified. The production enterprise needs to re-negotiate with the designated medical institution to request the purchase; Cancer drug, not submitted to Sunshine Platform before September 30, 2018 drug The price adjustment filing form will suspend its procurement eligibility.

On August 24th, the implementation plan for the centralized procurement of anticancer drugs in Shandong Province was released to the public. According to the notice, Shandong Province will adopt competitive quotation, quantity negotiation, direct net connection, etc. according to the number of enterprises to declare, and implement classified procurement. The cycle is in principle 1 year.

It is understood that Shandong Province implements a two-round quotation system for production enterprises in the competitive quotation. The production enterprises comprehensively consider canceling import tariffs and reducing the value-added tax and other factors for the first round of independent quotation. In principle, they should not be higher than the respective provinces of the country. The minimum purchase price at the provincial level, the drug that passed the consistency evaluation shall not be higher than the minimum purchase price adjusted by the province according to the relevant regulations. If the number of production enterprises that have passed the consistency evaluation of the same specifications reaches 3 or more, no other unsuccessful acceptance is accepted. In addition, for the declaration of drugs declared by only one or two production enterprises, the medical institutions will jointly negotiate and purchase the goods, and negotiate the transaction price as the maximum purchase price limit for medical institutions.

Prior to this, Jiangxi Province medicine On August 13th, the Purchasing Service Center issued a notice to solicit the opinions on the implementation plan for the special procurement of anticancer drugs in Jiangxi Province in 2018 (draft for comments).